Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Common Equity (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Common Equity data on record, last reported at $189.5 million in Q4 2025.

  • For Q4 2025, Common Equity rose 20.27% year-over-year to $189.5 million; the TTM value through Dec 2025 reached $189.5 million, up 20.27%, while the annual FY2025 figure was $189.5 million, 20.27% up from the prior year.
  • Common Equity reached $189.5 million in Q4 2025 per ARQT's latest filing, up from $158.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $451.0 million in Q1 2021 and bottomed at $46.7 million in Q3 2023.
  • Average Common Equity over 5 years is $208.3 million, with a median of $188.0 million recorded in 2024.
  • Peak YoY movement for Common Equity: tumbled 82.75% in 2023, then skyrocketed 235.3% in 2024.
  • A 5-year view of Common Equity shows it stood at $297.7 million in 2021, then fell by 29.59% to $209.6 million in 2022, then tumbled by 57.69% to $88.7 million in 2023, then soared by 77.68% to $157.5 million in 2024, then rose by 20.27% to $189.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $189.5 million in Q4 2025, $158.1 million in Q3 2025, and $139.0 million in Q2 2025.